# 2025-22540: DEA Plays Whack-A-Mole With Unpronounceable Designer Drug

2025-22540, Schedules of Controlled Substances: Extension of Temporary Placement of MDMB-4en-PINACA in Schedule I of the Controlled Substances Act, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2025-12-11, effective 2025-12-12 (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2025-22540
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-22540
- Title: Schedules of Controlled Substances: Extension of Temporary Placement of MDMB-4en-PINACA in Schedule I of the Controlled Substances Act
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 57356
- Published: 2025-12-11
- Effective: 2025-12-12
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Plays Whack-A-Mole With Unpronounceable Designer Drug

## Summary

The DEA is extending the temporary ban on MDMB-4en-PINACA, a powerful synthetic drug, keeping it in the strictest control category (Schedule I) for another year until December 12, 2026, or until a permanent decision is made. This means anyone making, selling, or using this drug faces serious legal consequences. The extension helps keep communities safe while the government finishes its review.

## Abstract

The Administrator of the Drug Enforcement Administration is issuing this temporary scheduling order to extend the temporary schedule I status of MDMB-4en-PINACA. The schedule I status of MDMB- 4en-PINACA is in effect through December 12, 2025. This temporary order will extend the temporary scheduling of MDMB-4en-PINACA for one year, or until the permanent scheduling action for this substance is completed, whichever occurs first. As a result of this order, the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances will continue to be imposed on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle MDMB-4en-PINACA.

## Effects PRIA read

- Schedule I Status Extended One Year: cost, high. The DEA extended the temporary Schedule I listing for MDMB-4en-PINACA effective December 12, 2025 through December 12, 2026, or until a permanent decision is made. That means anyone who makes, sells, imports, exports, or possesses this drug continues to face the regulatory controls and civil and cr…
- Research and Teaching Still Restricted: cost, medium. Researchers, educators, and laboratories that engage in research, instructional activities, or chemical analysis involving MDMB-4en-PINACA remain subject to Schedule I controls and to the same administrative, civil, and criminal sanctions. Those activities remain restricted under this temporary ord…
- Salts and Isomers Also Controlled: cost, medium. The temporary extension explicitly covers MDMB-4en-PINACA as well as its salts, isomers, and salts of isomers whenever such variants exist. That means chemical variants of MDMB-4en-PINACA are treated the same as the named compound under Schedule I during the extension period.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-22540 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/11/2025-22540/schedules-of-controlled-substances-extension-of-temporary-placement-of-mdmb-4en-pinaca-in-schedule-i)
- [2025-22540 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-11/pdf/2025-22540.pdf)

## Related
- [Previous: 2025-22518, Safety Zone; Patapsco River, Baltimore, MD](https://policyrisk.com/federal-register/2025-22518)
- [Next: 2025-22545, Magnuson-Stevens Act Provisions; Fisheries of the Northeastern United States; F…](https://policyrisk.com/federal-register/2025-22545)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-22540 (as of 2026-06-11).
